| |
Anticancer drug
|
Dosagea (min ~ max)
|
Urinary unchanged drug excretion rate (% of dosage/24h)b
|
Urinary unchanged drug concentrationc (μg/mL)
|
Dripping concentration (μg/mL)
|
|---|
|
Alkylating drug
|
CPA
|
500mg/m2 – 60mg/kg
|
10.0
|
50.0 – 201.2
|
2,000
|
|
IFM
|
0.8 – 3g/m2
|
6.0
|
48.0 – 180.0
|
1,000
|
|
Platinum drug
|
CBDCA
|
300 – 635mg/m2
|
57.0 – 82.0
|
171.0 – 520.7
|
5,000
|
|
CDDP
|
10 – 100mg/m2
|
14.0 – 54.0
|
1.4 – 54.0
|
100
|
|
Antimetabolite drug
|
MTX
|
10mg/body – 300mg/kg
|
75.0 – 98.0(72h)
|
1.4 – 3285.5
|
6,000
|
|
5-FU
|
5mg/kg – 2600mg/m2
|
10.0
|
16.8 – 260
|
1,000
|
|
Ara-C
|
0.8mg/kg – 3,000mg/m2
|
7.1 – 7.8
|
1.9 – 234
|
1,000
|
|
GEM
|
1,000 – 1,250mg/m2
|
5.3
|
53.0 – 66.3
|
300
|
|
Anthracycline drug
|
ADR
|
0.2mg/kg – 80mg/m2
|
11.5
|
0.8 – 9.2
|
1,000
|
|
Epi-ADR
|
15 – 100mg/m2
|
6.2 (48h)
|
0.5 – 3.0
|
1,000
|
|
Taxane drug
|
PTX
|
80 – 210mg/m2
|
7.3 – 11.3(72h)
|
1.9 – 7.9
|
200
|
|
DTX
|
60 – 75mg/m2
|
1.7 – 4.2 (48h)
|
0.5 – 1.6
|
200
|
|
Topoisomerase inhibitor
|
VP-16
|
60 – 500mg/m2
|
10.3 – 35.2
|
6.2 – 176.0
|
500
|
|
CPT-11
|
20 – 180mg/m2
|
16.3 – 21.1
|
3.3 – 38.0
|
1,500
|
-
a; Insurance application dose in Japan, b; Report value in each pharmaceutical products IF, c;Dosege × Japanease standard body surface area (1.73m2) or body weight (58kg) × urinary unchanged drug excretion rate ÷standard urine volume (1,730mL/day)
